Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrazole SCHEMBL735500 | 1.00 | HTR2A (0.34) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL225087 | 1.00 | HTR2A (0.34) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL526238 | 0.99 | HTR2A (0.33) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL5145009 | 0.90 | HTR2A (0.31) | HTR2AHTR1AHTR2CHTR2B | |
| O-Tolylamine SCHEMBL7116171 | 0.88 | HTR2A (0.32) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL23488 | 0.88 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL29356973 | 0.88 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL5058499 | 0.86 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| Ammonia Solution, Strong SCHEMBL20492883 | 0.86 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL17668115 | 0.86 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105385757-B | Method and kit for room temperature in situ detection of target nucleic acid in biological sample | 塞雷公司 | 2020-04-03 | — | — | CN | disclosed |
| US-20060216761-A1 | Isolation material for hormone disrupting substance, method of concentrating and method of clean-up | JAPAN ENVIROCHEMICALS, LTD. (JP) | 2006-09-28 | — | — | US | disclosed |
| US-20050136492-A1 | Affinity labeling of enzymes for detection of enzyme activity level in living cells | IMMUNOCHEMISTRY TECHNOLOGIES, LLC | 2005-06-23 | — | — | US | disclosed |
| EP-1514597-A1 | ISOLATION MATERIAL FOR HORMONE DISRUPTING SUBSTANCE, METHOD OF CONCENTRATING AND METHOD OF CLEAN-UP | Japan Envirochemicals, Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20050019833-A1 | Proteins capable of binding to environmental hormones and process for producing the same | JAPAN ENVIROCHEMICALS, LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1482043-A1 | PROTEINS CAPABLE OF BINDING TO ENVIRONMENTAL HORMONES AND PROCESS FOR PRODUCING THE SAME | Japan Envirochemicals, Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6720409-B2 | USEFUL IN THE DIAGNOSIS AND TREATMENT OF INFLUENZA A VIRUS | TAKARA SHUZO CO., LTD. (JP) | 2004-04-13 | — | — | US | disclosed |
| WO-2003058194-A2 | AFFINITY LABELING OF ENZYMES FOR DETECTION OF ENZYME ACTIVITY LEVEL IN LIVING CELLS | IMMUNOCHEMISTRY TECHNOLOGIES, LLC (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20020054882-A1 | Anti-human influenza virus antibody | TAKARA BIO INC. (JP) | 2002-05-09 | — | — | US | disclosed |
| EP-1003545-A4 | HEPARIN-BINDING GROWTH FACTOR (HBGF) POLYPEPTIDES | CHILDRENS HOSP RES FOUNDATION (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-1999007407-A1 | HEPARIN-BINDING GROWTH FACTOR (HBGF) POLYPEPTIDES | CHILDRENS HOSPITAL RESEARCH FOUNDATION (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1997031268-A1 | CHROMATOGRAPHIC STRIP HAVING DETECTION AND CONTROL ZONES ORIENTED PARALLEL TO THE DIRECTION OF FLOW | UNIVERSAL HEALTHWATCH, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5631350-A | Anti-human influenza virus antibody | TAKARA SHUZO CO., LTD. (JP) | 1997-05-20 | — | — | US | disclosed |
| US-5589174-A | DIAGNOSIS AND TREATMENT OF INFLUENZA A VIRUS, VACCINE | TAKARA SHUZO CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| EP-0621339-A2 | Immunogenic human influenza A virus haemagglutinin polypeptides | TAKARA SHUZO CO. LTD. (JP) | 1994-10-26 | — | — | EP | disclosed |
| US-5075078-A | SELF-PERFORMING IMMUNOCHROMATOGRAPHIC DEVICE | ABBOTT LABORATORIES (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0429470-A1 | ANTIBODY RECOGNITION OF FRAGMENTS FROM CYTOMEGALOVIRUS | THE CHILDREN'S HOSPITAL, INCORPORATED (US) | 1991-06-05 | — | — | EP | disclosed |
| WO-1990006771-A1 | PROTEOLYTIC FRAGMENTS OBTAINED FROM HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN COMPLEX I | THE CHILDREN'S HOSPITAL, INCORPORATED (US) | 1990-06-28 | — | — | WO | disclosed |
| WO-1990000062-A1 | ANTIBODY RECOGNITION OF FRAGMENTS FROM CYTOMEGALOVIRUS | THE CHILDREN'S HOSPITAL, INCORPORATED (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0251527-A2 | Haptenylated reagents and immunoassays | Panab Laboratories, Inc. (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019833-A1 | Proteins capable of binding to environmental hormones and process for producing the same | SHBG, SERPINA6, NR5A1 | HTR2A 1853/4885HTR1A 2995/4885HTR2C 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.